Trebananib

BIOLOGICAL9 trials

Sponsors

Amgen, Gynecologic Oncology Group, National Cancer Institute (NCI), Roswell Park Cancer Institute, Dana-Farber Cancer Institute

Conditions

Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)

Phase 1

Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors

CompletedNCT01538095

National Cancer Institute (NCI)Central Nervous System Neoplasm, Solid Neoplasm

Start: 2012-02-29End: 2016-04-30Updated: 2016-10-03

Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

CompletedNCT01548482

National Cancer Institute (NCI)Adult Solid Neoplasm, Lung Carcinoid Tumor, Recurrent Digestive System Neuroendocrine Tumor G1 +8

Start: 2012-03-31End: 2014-01-31Updated: 2015-10-06

Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia

CompletedNCT01555268

Roswell Park Cancer InstituteAdult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a) +13

Start: 2011-10-31End: 2016-08-03Updated: 2022-09-13

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

CompletedNCT03239145

Dana-Farber Cancer InstituteAdvanced Solid Tumor

Start: 2018-05-01End: 2024-12-13Updated: 2026-07-01

Phase 2

AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib

CompletedNCT00853372

AmgenAdvanced Renal Cell Carcinoma

Start: 2009-05-28End: 2019-06-25Updated: 2020-07-01

Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer

CompletedNCT01210222

Gynecologic Oncology GroupEndometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma +4

Start: 2011-06-06End: 2016-07-16Updated: 2018-02-23

Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

CompletedNCT01609790

National Cancer Institute (NCI)Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma +3

Start: 2012-06-04End: 2022-05-20Updated: 2022-07-21

Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery

CompletedNCT01623869

National Cancer Institute (NCI)Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma +1

Start: 2012-07-31End: 2015-02-28Updated: 2015-10-19

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

CompletedNCT01664182

National Cancer Institute (NCI)Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7 +1

Start: 2012-08-01End: 2020-12-07Updated: 2022-06-07

Related Papers

A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer

Cancer Immunology Research2024-09-303 citations

Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial

Journal for ImmunoTherapy of Cancer2021-11-0116 citations

808 Exploring resistance mechanism to pembrolizumab and ang-2 inhibitor trebananib (NCT03239145) using high-dimensional single-cell mass cytometry (CyTOF)

2020-11-01

Phase Ib study to test the safety and activity of pembrolizumab (anti-PD-1) and trebananib (angiopoietin-2 inhibitor [Ang-2]) in patients with advanced solid tumors: Updated analysis of the colorectal cancer (CRC) cohort.

Journal of Clinical Oncology2020-02-012 citations

Phase Ib study of pembrolizumab and trebananib (angiopoietin-2 inhibitor [Ang-2]): Preliminary analysis of the colorectal cancer (CRC) cohort.

Journal of Clinical Oncology2019-05-208 citations

Randomized phase 2 study of trebananib (AMG 386) with or without continued anti-vascular endothelial growth factor (VEGF) therapy in patients (pts) with renal cell carcinoma (RCC) who have progressed on bevacizumab, pazopanib, sorafenib, or sunitinib.

Journal of Clinical Oncology2016-05-201 citations

Phase 1 study of the angiopoietin 1/2 neutralizing peptibody, trebananib, in acute myeloid leukemia.

Journal of Clinical Oncology2014-05-205 citations

Alliance A091103: A multicenter phase II study of the angiopoietin-1 and -2 peptibody trebananib (AMG386) for the treatment of angiosarcoma (AS).

Journal of Clinical Oncology2014-05-20

Clinical and Biologic Effects Of The Angiopoietin 1/2 Neutralizing Peptibody, Trebananib (AMG 386), In Acute Myeloid Leukemia Patients

Blood2013-11-155 citations